A new study comparing the clinical effectiveness of anti–tumor necrosis factor agents and the interleukin-6 inhibitor tocilizumab (Acterma) in patients with rheumatoid arthritis found that tocilizumab outperformed anti-TNFs in terms of effectiveness and drug survival.
A new study comparing the clinical effectiveness of anti—tumor necrosis factor (TNF) agents and the interleukin-6 (IL-6) inhibitor tocilizumab (Acterma) in patients with rheumatoid arthritis (RA) found that tocilizumab outperformed anti-TNFs in terms of effectiveness and drug survival.
In the global, comparative, observational study, ACT-iON, funded by Roche and published in Arthritis Care and Research, patients with moderate to severe rheumatoid arthritis (n = 1216) who initiated biologic therapy after responding inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) were observed in routine clinical practice for 52 weeks after starting treatment with intravenous tocilizumab or an anti-TNF agent.
Data were collected between February 2012 and February 2015. The primary observation was the mean change from baseline in the Disease Activity Score 28 scale using erythrocyte sedimentation rate values (DAS28-ESR) at week 24. Secondary outcome measures included mean change from baseline in DAS28-ESR at week 52, swollen joint count (SJC), tender joint count (TJC), remission rates according to DAS28-ESR and the Clinical Disease Activity Index (CDAI), and patient-reported outcomes (PROs). Safety was assessed by monitoring adverse events (AEs), abnormalities in laboratory assessments, and vital signs.
Tocilizumab was initiated in 35% of patients (n = 423), and anti-TNF agents were initiated in 65% (n = 793).
In the anti-TNF arm, patients received the following biologics:
Patients initiating tocilizumab had a shorter mean disease duration than those initiating anti-TNF agents , as well as a slightly higher mean DAS28-ESR and SJC, and more frequent oral corticosteroid use. In the tocilizumab arm, 73.8% of patients received conventional synthetic DMARDs together with biologic therapy, as did 85.6% of patients receiving anti-TNF agents. Methotrexate was the most common concomitant DMARD.
The researchers found, with a 95% confidence interval (CI), the following:
In terms of drug survival, 14.9% of patients who initiated tocilizumab and 27.4% of those who started treatment with anti-TNF agents terminated biologic therapy
AEs and serious AEs were reported in similar proportions and rates between the 2 groups. The most common AEs were infections and infestations. Serious infections were reported in 8 (1.9%) of those receiving tocilizumab and 26 (3.3%) of those receiving anti-TNF agents. Three patients in the tocilizumab group died (2 of pneumonia, 1 of cardiac failure), and 6 patients in the anti-TNF group died (causes of death included sepsis, pneumonia, and pericardial effusion).
The researchers concluded that patients who initiated biologic treatment with tocilizumab experienced better drug survival and better clinical improvements than did those who initiated biologic treatment with anti-TNF agents.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Meta-Analysis Confirms Similar Safety, Efficacy Between Adalimumab Biosimilars, Humira
April 6th 2024A systematic review and meta-analysis of 7 randomized controlled trials found no significant differences in efficacy and safety indicators between adalimumab biosimilars and the reference product (Humira) for treatment of moderate to severe psoriasis.